Prevention of Seasonal Affective Disorder

Seasonal Affective Disorder (SAD) Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00046449
• Other study ID #: 398149
• Status: Completed
• Phase: Phase 3
• First received: September 30, 2002
• Last updated: June 2, 2015
• Start date: September 2002
• Est. completion date: June 2003

Study information

• Verified date: June 2015
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

A Placebo Controlled Study Evaluating The Effectivess Of Medication In Preventing Seasonal Affective Disorder

Other known NCT identifiers

• NCT00300144

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: June 2003
• Est. primary completion date: June 2003
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria: (Patient must meet these criteria in order to be eligible for this study.)

• Patient has a history of Major Depressive Disorder (MDD) with a seasonal pattern.

Exclusion Criteria: (Patient cannot meet these criteria in order to be eligible for this study.)

• Patient has a current or past history of seizure disorder or brain injury.

• Patient has a history or current diagnosis of anorexia nervousa or bulimia.

• Patient has recurrent summer depression more frequently than winter depression.

• Patient has primary diagnosis of panic disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD), acute distress disorder, bipolar II disorder or other psychotic disorders.

• Patient has initiated psychotherapy within the last 3 months.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Mood Disorders
• Seasonal Affective Disorder
• Seasonal Affective Disorder (SAD)

Intervention

Drug:
• Investigational Seasonal Affective Disorder (SAD) Drug

Locations

Country	Name	City	State
Canada	Study Site	Edmonton	Alberta
Canada	Study Site	Hull	Quebec
Canada	Study Site	Markham	Ontario
Canada	Study Site	Miramichi	New Brunswick
Canada	Study Site	Mississauga	Ontario
Canada	Study Site	Sydney	Nova Scotia
Canada	Study Site	Vancouver	British Columbia
United States	Study Site	Allentown	Pennsylvania
United States	Study Site	Amityville	New York
United States	Study Site	Boise	Idaho
United States	Study SIte	Chicago	Illinois
United States	Study Site	Chicago	Illinois
United States	Study Site	Cincinnati	Ohio
United States	Study Site	Cleveland	Ohio
United States	Study Site	Cleveland	Ohio
United States	Study Site	Eugene	Oregon
United States	Study Site	Florence	Kentucky
United States	Study SIte	Greenwood	Indiana
United States	Study Site	Hoffman Estates	Illinois
United States	Study Site	Homer	Alaska
United States	Study Site	Independence	Ohio
United States	Study Site	Indianapolis	Indiana
United States	Study Site	Lawrence	New York
United States	Study Site	Libertyville	Illinois
United States	Study Site	Lincoln	Rhode Island
United States	Study Site	Lyndhurst	Ohio
United States	Study Site	Madison	Wisconsin
United States	Study Site	Middleton	Wisconsin
United States	Study Site	Milwaukee	Wisconsin
United States	Study Site	Minneapolis	Minnesota
United States	Study Site	Moorestown	New Jersey
United States	Study Site	New Haven	Connecticut
United States	Study Site	New York	New York
United States	Study Site	Newark	Delaware
United States	Study SIte	Northfield	Illinois
United States	Study Site	Okemos	Michigan
United States	Study Site	Olean	New York
United States	Study Site	Philadelphia	Pennsylvania
United States	Study Site	Philadelphia	Pennsylvania
United States	Study Site	Piscataway	New Jersey
United States	Study Site	Portland	Oregon
United States	Study Site	Portland	Oregon
United States	Study Site	Royal Oak	Michigan
United States	Study Site	Salem	Oregon
United States	Study Site	Schaumburg	Illinois
United States	Study Site	Seattle	Washington
United States	Study Site	Staten Island	New York
United States	Study Site	Toledo	Ohio
United States	Study Site	Washington	District of Columbia
United States	Study Site	Washington	District of Columbia
United States	Study Site	Wellesley Hills	Massachusetts
United States	Study Site	West Allis	Wisconsin
United States	Study Site	Williamsville	New York
United States	Study Site	Wilmington	Delaware

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Canada,